Finished
Hybrid Assistive Limb Application in Multiple Sclerosis Patients
NCT07326852 · Ege University · Updated 7 July 2026
- What is being tested
- Hybrid Assistive Limb (HAL)
- For
- Multiple Sclerosis
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 50 years. About 13 people. The full rules are on the registry page.
- Where
- Turkey (Türkiye)
- When
- Starts or started 8 Oct 2025, ends 9 Feb 2026. Registered 8 Jan 2026.
- Results
- None posted yet.
In the researchers' words
The Hybrid Assistive Limb (HAL) exoskeleton detects bioelectrical signals from the muscles, responds to the intention of voluntary movement, and provides biological feedback. In this study, the effects of HAL application on walking performance and balance in patients with multiple sclerosis will be examined in a single-center, controlled design. Participants will undergo walking rehabilitation with HAL for 1 hour per day, 5 days a week, for a total of 2 months. Walking and balance performance will be assessed before and after the intervention using the 10-Minute Walk Test (10MWT) to measure maximum walking speed, the 6-Minute Walk Test (6MWT) to evaluate walking endurance and cardiorespiratory performance, and the Timed Up and Go Test (TUG) to assess functional mobility and dynamic balance. Additionally, walking parameters and static balance will be measured using Tecnobody systems. Appropriate statistical tests will be applied, and a significance level of p\<0.05 will be considered.
Sites
- Ege UniversityIzmir, Karşıyaka, Turkey (Türkiye)
